住院非重症社区获得性肺炎一线与替代抗生素方案的比较效果:多中心回顾性队列研究
该多中心回顾性队列研究纳入2015至2021年加拿大19家医院收治的23,512例非重症社区获得性肺炎(CAP)住院患者,比较β-内酰胺联合大环内酯(BL+M)、单用β-内酰胺(BL)、呼吸喹诺酮(FQ)或β-内酰胺联合多西环素(BL+D)对院内死亡率的影响。结果显示BL+M、FQ和BL+D结局相似,均可作为有效方案;与BL+M相比,BL与更长的出院时间相关,且死亡风险置信区间不能排除小幅但有临床意义的增加。
要点
- BL+M、FQ和BL+D治疗非重症CAP的院内死亡率相似,均可考虑为有效方案。
- 与BL+M相比,单用BL与更长的出院时间相关(sHR 0.90,95%CI 0.84-0.96)。
- 单用BL的死亡风险置信区间不能排除小幅但有临床意义的增加。
核心结论
- BL+M、FQ和BL+D治疗非重症CAP的结局相似,可视为有效方案。
- 与BL+M相比,BL与更长的出院时间相关,且死亡风险置信区间不能排除小幅但临床重要的增加。
研究设计与样本
- 多中心回顾性队列研究,纳入2015至2021年加拿大19家医院连续收治的CAP住院患者。
- 采用目标试验方法,按入院48小时内初始抗生素分为BL+M、BL、FQ、BL+D四组。
- 排除入院48小时内需ICU的重症CAP患者,使用倾向评分和重叠权重平衡协变量。
主要发现
- 共23,512例患者,BL+M组9,340例(39.7%),BL组9,146例(38.9%),FQ组4,510例(19.2%),BL+D组516例(2.2%)。
- 院内死亡:BL+M组703例(7.5%),BL组888例(9.7%),FQ组302例(6.7%),BL+D组31例(6.0%)。
- 与BL+M相比的调整风险差:BL为1.5%(95%CI -0.3%至3.3%),FQ为-0.9%(95%CI -2.9%至1.1%),BL+D为-1.9%(95%CI -4.8%至0.9%)。
- 与BL+M相比,存活出院subdistribution hazard ratio:BL为0.90(95%CI 0.84-0.96),FQ为1.07(95%CI 0.99-1.16),BL+D为1.04(95%CI 0.93-1.17)。
临床怎么用
- 对于住院非重症CAP患者,BL+M、FQ和BL+D均可作为有效初始方案。
- 选择单用BL时需权衡其与更长出出院时间和可能小幅增加的死亡风险。
局限性
- 回顾性队列设计可能存在残余混杂。
- BL+D组样本量较小(516例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There are several antibiotic regimens to treat community-acquired pneumonia (CAP). RESEARCH QUESTION: In patients hospitalized to a non-ICU ward setting with CAP, is there a difference between first-line and alternative antibiotic regimens (β-lactam plus macrolide [BL+M], β-lactam [BL] alone, respiratory fluoroquinolone [FQ], or β-lactam plus doxycycline [BL+D]) in terms of in-hospital mortality? STUDY DESIGN AND METHODS: This retrospective cohort study included consecutive patients admitted with CAP at 19 Canadian hospitals from 2015 to 2021. Taking a target trial approach, patients were categorized into the four antibiotic groups based on the initial antibiotic treatment within 48 h of admission. Patients with severe CAP requiring ICU admission in the first 48 h were excluded. The primary outcome was all-cause in-hospital mortality. Secondary outcome included time to being discharged alive. Propensity score and overlap weighting were used to balance covariates. RESULTS: Of 23,512 patients, 9,340 patients (39.7%) received BL+M, 9,146 (38.9%) received BL, 4,510 (19.2%) received FQ, and 516 (2.2%) received BL+D. The number of in-hospital deaths was 703 (7.5%) for the BL+M group, 888 (9.7%) for the BL group, 302 (6.7%) for the FQ group, and 31 (6.0%) for the BL+D group. The adjusted risk difference for in-hospital mortality when compared with BL+M was 1.5% (95% CI, -0.3% to 3.3%) for BL, -0.9% (95% CI, -2.9% to 1.1%) for FQ, and -1.9% (95% CI, -4.8% to 0.9%) for BL+D. Compared with BL+M, the subdistribution hazard ratio for being discharged alive was 0.90 (95% CI, 0.84-0.96) for BL, 1.07 (95% CI, 0.99-1.16) for FQ, and 1.04 (95% CI, 0.93-1.17) for BL+D. INTERPRETATION: BL+M, FQ, and BL+D had similar outcomes and can be considered effective regimens for nonsevere CAP. Compared with BL+M, BL was associated with longer time to discharge and the CI for mortality cannot exclude a small but clinically important increase in risk.
引用
- Bai, Srivastava, Wong, et al. Comparative Effectiveness of First-Line and Alternative Antibiotic Regimens in Hospitalized Patients With Nonsevere Community-Acquired Pneumonia: A Multicenter Retrospective Cohort Study. Chest. 2023. PMID: 37574164. doi:10.1016/j.chest.2023.08.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。